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show me the in vivo targets
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Microorganisms that cause persistent infection often exhibit specific 
adaptations that allow them to avoid the adaptive immune response. Recently, 
several bacterial toxins have been shown in vitro to disrupt immune cell 
functions. However, it remains to be established whether these activities are 
relevant during infection and whether these toxins have specifically evolved to 
disrupt the adaptive immune system.
 
Bacterial pathogens, particularly those
that have coevolved extensively with
their hosts, possess a vast array of fine-
tuned determinants that are capable of
modulating a variety of cellular func-
tions. Often described as “toxins,” “mod-
ulins,” or “effectors,” these bacterial pro-
ducts posses precise biochemical activities,
which allow them to stimulate or inter-
fere with a variety of cellular processes
(1). Delivery of these bacterial effec-
tors of virulence is mediated by an
equally diverse set of specific adapta-
tions. These adaptations include acces-
sory proteins (referred to as toxin “B”
subunits) that target specific receptors
and vesicular trafficking pathways to
deliver the enzymatically active compo-
nents (known as toxin “A” subunits) to
the appropriate cellular location (2), as
well as more complex organelles that
act as injection devices for the direct
delivery of the toxins (such as the type
III and type IV secretion systems; refer-
ence 3). Bacterial toxins have attracted
a lot of attention from scientists, particu-
larly those toxins whose powerful effects
have conferred for them a special place
in the annals of microbiology, such as
the botulinum, diphteria, and anthrax
toxins. Consequently, the understand-
ing of the biochemical activities of bac-
terial toxins has traditionally been far
ahead of the understanding of the patho-
genesis of the microorganisms that pro-
duce them.
When investigating a bacterial toxin,
it is important to consider its biochem-
ical activity as well as its potential tar-
get(s) within the host cell and potential
target cell(s) within the host. It is also
important to consider its function in
the context of the toxin’s role during
the pathogenesis of the bacterium that
produces it. The field of toxinology has
been remarkably successful in identify-
ing the biochemical activities of many
bacterial toxins and reasonably success-
ful at defining some of their potential tar-
gets within the host cell. Protein toxins
that exert their activity as proteases,
phosphatases, ADP ribosylases, ade-
nylate cyclases, guanine nucleotide ex-
change factors, GTPase-activating pro-
teins, and nucleases have been described
(2, 4–6). In addition, in many instances
the intracellular targets of these bio-
chemical activities have been identified.
However, identifying the cell type(s)
targeted during infection and establish-
ing the actual role of these toxins in
pathogenesis is difficult. Consequently,
little is known about these important
aspects of toxin biology. This is even
the case for toxins whose biochemical
mechanism has been known for many
years. Notable exceptions are toxins
such as tetanus and botulinum toxin,
which cause such a distinct neurological
pathology in vivo that the identification
of the relevant cellular targets was greatly
facilitated (7).
 
Targeting T cells
 
In this issue of the 
 
JEM
 
, two articles
describe a potential role for two bacterial
toxins in the modulation of the immune
system by interfering with T cell sig-
naling. Using an in vitro Jurkat T cell
system, Gerke et al. (8) report that 
 
Yer-
sinia pseudotuberculosis
 
 inhibits T cell ac-
tivation and that the inhibitory activity
was strictly dependent on the 
 
Yersinia
 
outer protein H (YopH), a potent ty-
rosine phosphatase that is delivered to
host cells by a bacterially encoded type
III protein secretion system. Previous
studies by a number of laboratories
have identified several tyrosine phos-
phorylated proteins as apparent targets
for the tyrosine phosphatase activity of
YopH in cell culture systems. These
include p130Cas, focal adhesion kinase,
and paxillin in HeLa cells, and Fyb/
SLAP130, p130Cas, and SKAP55 in
macrophages (9–12). In general, these
are proteins involved in integrin signal-
ing, which is consistent with the pro-
posed role of YopH as an antiphago-
cytic molecule. More recent studies
have shown that YopH can also inhibit
T cell signaling in-vitro and that this ac-
tivity could be correlated with the pres-
ence of YopH and the dephosphoryla-
tion of the tyrosine kinase Lck (13).
Gerke et al. (8) have now extended
those studies and added the T cell–
signaling adaptor proteins LAT and
SLP-76 to the list of potential YopH
substrates. These adaptor proteins are
essential for the transduction of signals
from the T cell receptor and its associ-
ated tyrosine kinases, and their tyrosine
phosphorylation is required for their
activities. Consequently, Gerke et al. (8)
argue that tyrosine dephosphorylation
of these adaptor proteins by YopH is
responsible for the observed inhibition
of T cell receptor signaling after 
 
Yer-
sinia
 
 infection of cultured Jurkat T cells.
They also present data that argue that
both of these proteins are high affinity
substrates of YopH, presumably requir-
ing small amounts of translocated toxin
to be targeted for dephosphorylation.
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In the second article, Rossi Paccani
et al. (14) report that anthrax toxin also
disrupts T cell signaling but by a com-
pletely different mechanism. Anthrax
toxin, which is produced by 
 
Bacillus an-
thracis
 
, is composed of two enzymatic
or A subunits known as edema factor
(EF) and lethal factor (LF) that alter-
natively associate with a B subunit,
known as protective antigen, which
mediates their delivery into target cells
(15). EF is a potent calcium/calmodu-
lin-dependent adenylate cyclase, which
causes a massive increase of cyclic AMP
in intoxicated cells and global disrup-
tion of cell signaling. LF is a zinc-
dependent protease that specifically
disrupts the mitogen-activated protein
(MAP) kinase signaling pathways by
cleaving the activating MAP kinase ki-
nases MEK1/2 and MKK3, MKK4,
MKK6, and MKK7 (16–19). Rossi
Paccani et al. (14) showed that treat-
ment of peripheral blood lymphocytes
with protective antigen in combina-
tion with either LF or EF effectively
blocked T cell signaling as measured by
the expression levels of the surface acti-
vation markers CD69 and CD25, the
production of cytokines, and cell pro-
liferation. Given the ubiquitous pres-
ence of the anthrax toxin receptors and
the essential role for MAP kinases and
cAMP in T cell signaling, the results
presented by Rossi Paccani et al. (14)
are expected.
 
In vivo targets
 
The broader issue raised by these two
and other studies with other bacterial
toxins that disrupt immune cell func-
tion in vitro, however, is the in vivo
relevance of the findings. Have these
toxins evolved to specifically target T
cell signaling? Do these pathogens spe-
cifically interfere with T cell signaling
during the course of an infection? Un-
fortunately, in vitro studies, although
useful to provide testable hypotheses,
cannot provide answers to these impor-
tant questions.
In the case of YopH, Gerker et al.
(8) make a strong case for SLP-76 and
LAT as high affinity substrates for this ty-
rosine phosphatase and hence of poten-
tial relevance during infection when pre-
sumably the pathogen would deliver
small quantities of this toxin. Indeed, it is
often the case that under vitro experi-
mental conditions, cells are exposed to
toxin quantities not usually delivered
during actual infections. Nevertheless, it
is not known how much YopH is deliv-
ered by 
 
Yersinia
 
 during infection, and
there is no evidence demonstrating that
 
Yersinia
 
 hampers T cell function during
infection. 
 
Yersinia
 
 infections are usually
acute (20), arguing against the need for
these pathogens to counteract the host-
specific adaptive immune responses dur-
ing infection. However, although rare,
chronic infections are sometimes ob-
served (21, 22), and in those cases, the
ability to interfere with T cell function
might be useful to the pathogen. Whether
this function of YopH has been specifi-
cally selected by evolution or is simply a
“by-product” of another of its demon-
strated functions, such as disruption of
macrophages during acute infection, re-
mains to be established.
Anthrax toxin possesses even a more
difficult challenge because its biochem-
ical activity (such as inhibition of MAP
kinase signaling) can potentially affect
a large number of cellular processes.
Therefore, the ability of anthrax toxin
to inhibit MAP kinase signaling can re-
sult in the in vitro inhibition of any of
the rather large number of intracellular
signaling pathways that involve these
kinases, regardless of their relevance
during infection. For example, if added
to cultured neurons, anthrax toxin would
certainly prevent neurite outgrowth, a
process strictly dependent on MAP ki-
nase signaling (23). However, it would
be hard to argue that this is a relevant
function for the toxin during infection.
By the same token, anthrax toxin pre-
dictably inhibited in vitro T cell signal-
ing, a process strictly dependent on
MAP kinase signaling. However, more
experiments will be required to estab-
lish whether this activity of the toxin
is important during infection. If un-
treated, 
 
B. anthracis
 
 infections are usu-
ally hyper acute (24); therefore, inhib-
iting T cell signaling may not provide a
significant advantage to the pathogen.
On occasions, 
 
B. anthracis
 
 can be asso-
ciated with sub-acute infections (such
as cutaneous anthrax; reference 24), in
which case inhibition of T cell function
may provide some advantages to the
pathogen. In any case, because 
 
B. an-
thracis
 
 is most likely an “accidental”
pathogen of mammals, it is unlikely
that evolution may have played any
role in directly shaping the effects of
anthrax toxin on T cells. Therefore,
this activity might be more a byprod-
uct, relevant or not, of other activities
of this toxin in the normal ecology of
 
B. anthracis
 
.
Although every pathogen must con-
tend with the onslaught of the innate
immune responses, it is not necessarily
the case that every pathogen must
counteract the acquired immune re-
sponse to fulfill its replication program.
For most pathogens that cause acute in-
fections, their life cycle within the host
is most often over by the time the na-
ive host mounts a meaningful acquired
immune response capable of control-
ling the infection. In fact, most infec-
tions with pathogens that have co-
evolved with their hosts are indeed
asymptomatic, do not lead to overt
harm, and most often result in protec-
tive convalescent immunity. On the
other hand, pathogens that cause per-
sistent infections might be under strong
evolutionary pressure to evolve specific
mechanisms to avoid acquired immune
responses. Indeed, mechanisms of anti-
genic variation or specific inhibition of
antigen presentation evolved by micro-
bial pathogens are well documented
(25). For example, many viral patho-
gens specifically interfere, by a variety
of mechanisms, with both major histo-
compatibility class I and II antigen-pre-
senting pathways (26, 27). In addition,
many viral, bacterial, and protozoan
pathogens undergo rapid antigenic vari-
ation to evade the onslaught of the
acquired immune response (28–30).
Whether inhibition of T cell signaling
by anthrax or YopH toxins should be
added to the list of pathogenic mecha-
nisms specifically evolved to counter
the acquired immune response awaits
further in vivo experimentation.
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